Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review

Abstract

Biologic therapies have improved the management of rheumatoid arthritis (RA) and the treat-to-target approach has resulted in many patients achieving remission. In the current treatment landscape, clinicians have begun considering dose reduction/tapering for their patients. Rheumatology guidelines in Asia, Europe, and the United States include down-titration of biologics but admit that the level of evidence is moderate. We conducted a systematic literature review to assess the published studies that evaluate down-titration of biologics in RA. The published literature was searched for studies that down-titrated the following biologics: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab. Eligible studies included randomized controlled trials (RCTs), non-RCTs, observational, and pharmacoeconomic studies. The outcomes of interest were (1) efficacy and health-related quality of life, (2) disease flares, and (3) impact on cost. Eleven full-text publications were identified; only three were RCTs. Study results suggest that dosing down may be an option in many patients who have achieved remission or low disease activity. However, some patients are likely to experience a disease flare. Across the studies, the definition of disease flare and the down-titration criteria were inconsistent, making it difficult to conclude which patients may be appropriate and when to attempt down-titration. Studies have evaluated the practice of dosing down biologic therapy in patients with RA; however, a relatively small number of RCTs have been published. Although down-titration may be an option for some patients in LDA or remission, additional RCTs are needed to provide guidance on this practice.Electronic supplementary materialThe online version of this article (doi:10.1007/s00296-017-3780-8) contains supplementary material, which is available to authorized users.

Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

“…However, recommended strategies are not yet clearly defined and the consequences of such changes are not well understood. Cost-analysis studies clearly demonstrate that decreasing doses of bDMARDs decreases costs [18]. What remains unclear are the consequences for patients, both in terms of identifying the long-term consequences of extending dosing (radiographic changes, flares ...) as well as determining characteristics that may aid clinicians in identifying patients in which down-titration or discontinuation of bDMARDs may be possible [18].…”

Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations

“…108 On which patients down-titration of the biologic therapy should be considered or delayed. 109 Beyond merely clinical remission determined with tender and swollen joint counts, imaging or serologic remission may also be taken into account. 110 In a study on guidance of ultrasound for de-escalation of biologics, the presence of power Doppler positive synovitis in any joint at baseline was found to be predictive of flares.…”

Spectrum-Effect Relationships between Fingerprints of Caulophyllum robustum Maxim and Inhabited Pro-Inflammation Cytokine Effects

“…Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that results in swollen joints, pain, and the disorder of many tissues and organs [1]. RA may affect other parts of the body and even cause a low red blood cell count, as well as inflammation around the lungs and heart [2].…”